| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
260,040,000 |
| Market
Cap: |
103.36(B) |
| Last
Volume: |
682,467 |
Avg
Vol: |
1,619,368 |
| 52
Week Range: |
$323.57 - $446.08 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ BIOTECHNOLOGY |
| |
NASDAQ COMPOSITE |
|
NASDAQ-100 |
| |
S&P 400 MIDCAP |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 543 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
67,740 |
152,280 |
258,193 |
599,211 |
| Total Sell Value |
$28,555,052 |
$61,805,647 |
$99,413,137 |
$200,212,570 |
| Total People Sold |
8 |
12 |
15 |
18 |
| Total Sell Transactions |
28 |
41 |
68 |
132 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Altshuler David |
EVP, Global Research and CSO |
• – – |
2023-11-15 |
4 |
AS |
$369.92 |
$7,028 |
D/D |
(19) |
32,038 |
|
19% |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2023-11-14 |
4 |
AS |
$380.82 |
$2,151,633 |
D/D |
(5,650) |
29,302 |
|
13% |
|
| Kewalramani Reshma |
CEO & President |
• • – |
2023-11-13 |
4 |
AS |
$377.00 |
$1,921,569 |
D/D |
(5,097) |
113,809 |
|
10% |
|
| Sachs Bruce I |
Director |
– • – |
2023-11-06 |
4 |
AS |
$385.00 |
$4,331,250 |
D/D |
(11,250) |
40,000 |
|
7% |
|
| Sachs Bruce I |
Director |
– • – |
2023-11-06 |
4 |
OE |
$127.54 |
$1,434,825 |
D/D |
11,250 |
51,250 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2023-10-31 |
4 |
AS |
$355.92 |
$2,011,304 |
D/D |
(5,651) |
34,952 |
|
14% |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2023-10-17 |
4 |
AS |
$373.25 |
$2,109,236 |
D/D |
(5,651) |
40,603 |
|
15% |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2023-10-17 |
4 |
AS |
$375.00 |
$91,125 |
D/D |
(243) |
3,901 |
|
15% |
|
| Leiden Jeffrey M |
Executive Chairman |
• • – |
2023-10-16 |
4 |
AS |
$374.00 |
$4,847,788 |
D/D |
(12,962) |
22,425 |
|
16% |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2023-10-06 |
4 |
AS |
$360.00 |
$87,120 |
D/D |
(242) |
4,144 |
|
18% |
|
| Lagarde Michel |
Director |
– • – |
2023-10-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,132 |
1,132 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2023-10-03 |
4 |
AS |
$345.28 |
$1,951,177 |
D/D |
(5,651) |
46,254 |
|
21% |
|
| Biller Jonathan |
EVP and Chief Legal Officer |
• – – |
2023-10-02 |
4 |
AS |
$346.76 |
$211,524 |
D/D |
(610) |
10,569 |
|
22% |
|
| Biller Jonathan |
EVP and Chief Legal Officer |
• – – |
2023-09-29 |
4 |
D |
$350.72 |
$143,094 |
D/D |
(408) |
11,179 |
|
- |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2023-09-19 |
4 |
AS |
$351.00 |
$1,983,501 |
D/D |
(5,651) |
51,905 |
|
22% |
|
| Bozic Carmen |
EVP and CMO |
• – – |
2023-09-05 |
4 |
AS |
$352.66 |
$1,992,882 |
D/D |
(5,651) |
57,556 |
|
24% |
|
| Atkinson Edward Morrow Iii |
EVP, Chief Technical Ops. Off. |
• – – |
2023-08-29 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
13,879 |
|
19% |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2023-08-23 |
4 |
AS |
$355.00 |
$887,500 |
D/D |
(2,500) |
48,637 |
|
17% |
|
| Tatsis Ourania |
EVP, Chief Reg. & Quality Off. |
• – – |
2023-08-10 |
4 |
AS |
$345.79 |
$1,988,293 |
D/D |
(5,750) |
51,137 |
|
16% |
|
| Sachdev Amit |
EVP, Chief Patient Officer |
• – – |
2023-08-10 |
4 |
AS |
$350.00 |
$3,510,850 |
D/D |
(10,031) |
58,814 |
|
16% |
|
| Kearney Terrence C |
Director |
– • – |
2023-08-10 |
4 |
AS |
$350.00 |
$3,500,000 |
D/D |
(10,000) |
6,536 |
|
16% |
|
| Kearney Terrence C |
Director |
– • – |
2023-08-10 |
4 |
OE |
$127.54 |
$1,275,400 |
D/D |
10,000 |
16,536 |
|
- |
|
| Altshuler David |
EVP, Global Research and CSO |
• – – |
2023-08-09 |
4 |
AS |
$345.51 |
$21,767 |
D/D |
(63) |
32,038 |
|
19% |
|
| Bhatia Sangeeta N. |
Director |
– • – |
2023-08-09 |
4 |
AS |
$345.51 |
$83,613 |
D/D |
(242) |
4,386 |
|
19% |
|
| Sachs Bruce I |
Director |
– • – |
2023-07-17 |
4 |
AS |
$355.54 |
$4,013,459 |
D/D |
(11,250) |
40,000 |
|
-1% |
|
3258 Records found
|
|
Page 5 of 131 |
|
|
0.22 (0.06%) 
